Home › NCT05008146
Imaging CRF X NOP Interactions in CUD
Imaging Corticotrophin-releasing Factor (CRF) X Nociceptive Opioid Peptide (NOP) Interactions in Cocaine Use Disorders (Aim 1)
Who can join
Ages 18 to 55 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Cocaine use disorders (CUD) 1. Males or females between 18 and 55 years old 2. Fulfil DSM-5 criteria for cocaine use disorder 3. No other current DSM-5 psychiatric or addictive disorders (such as major depressive disorder, bipolar disorders, psychotic disorders, etc.,) 4. No current abuse (six months) of opiates, sedative-hypnotics, amphetamines, MDMA, etc., as well as moderate to severe alcohol or cannabis use (twice a week). Nicotine use will be quantified and controlled between groups using the Fagerstrom Test for Nicotine Dependence (Heatherton et al., 1991); 5. Not currently on prescription medical or psychotropic medications 6. No current or past severe medical, endocrine or neurological illnesses including glaucoma, seizure disorders, hypertension, hypercholesterolemia as assessed by a complete medical history and physical 7. Not currently pregnant or breastfeeding 8. No history of significant radioactivity exposure in past year from another research study or occupation that exceeds RDRC guidelines 9. No metallic objects in the body that are contraindicated for MRI Healthy Controls (HC) 1. Males or females between 18 and 55 years old 2. No present or past DSM-5 disorders (other than nicotine dependence) 3. Criteria 5 to 9 as listed previously.
About the study
This study uses \[11C\]NOP-1A positron emission tomography (PET) and a hydrocortisone challenge to image the interaction between nociceptive opioid peptide (NOP) receptors and cortisol/corticotrophin releasing factor (CRF) in subjects with cocaine use disorders (CUD) and matched healthy controls (HC). It will also examine whether alterations in CRF x NOP interactions predict relapse in subjects with CUD.
What is being tested
- Baseline [C-11]NOP-1A PET Scan (radiation)
- Hydrocortisone (drug)
- Post-hydrocortisone [C-11]NOP-1A PET Scan (radiation)
Sponsor: Rajesh Narendran · Participants: 80 · Started: Dec 31, 2020
Contact the study team
- Rajesh Narendran, MD · Phone: 4126475176
Official record on ClinicalTrials.gov — NCT05008146
Locations in the U.S.
| Pennsylvania | University of Pittsburgh, Pittsburgh |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.